Amgen hangs on to Kite in CAR-T race
This article was originally published in Scrip
Amgen is jumping into the CAR-T fray by signing a significant deal with Kite Pharma. The companies are partnering to develop novel chimeric antigen receptor T cell (CAR-T) immunotherapies based on Kite's engineered autologous cell therapy (eACT) platform and cancer targets from Amgen.
You may also be interested in...
Scrip spoke with Levy, senior vice president of global development, about the company's novel candidates for cardiovascular and inflammatory diseases and cancer, including modalities outside of its primary focus on biologics and small molecules.
Amgen is validating targets through the deCODE Genetics investment it made five years and moving drugs into the clinic. It's one of multiple technologies – along with its BiTE and oncolytic virus platforms – that R&D head Sean Harper said is starting to bear fruit for the company.
Amgen ended its own development of the CETP inhibitor AMG 899, but will see if anyone else wants to license the drug. Meanwhile, the company is focusing on new drugs and assets in development to offset declining sales for Enbrel and other blockbusters.